Literature DB >> 12107196

Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency.

Evangelia Charmandari1, Graeme Eisenhofer, Sarah L Mehlinger, Ann Carlson, Robert Wesley, Margaret F Keil, George P Chrousos, Maria I New, Deborah P Merke.   

Abstract

Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is characterized by decreased synthesis of glucocorticoids and mineralocorticoids, adrenal hyperandrogenism, and impaired development and function of the adrenal medulla. Although genotype can usually predict phenotype, genotype-phenotype discordance has been described. We investigated the association between adrenomedullary function, disease severity, and genotype in 37 children [22 males and 15 females; age range, 4.7-14.9 yr; 28 salt-wasting (SW) and 9 simple virilizing (SV) CAH] with classic 21-hydroxylase deficiency. Plasma and 24-h urinary catecholamines and their metabolites, and the 21-hydroxylase genotype were determined in all patients. The disease-causing mutations were divided into 4 groups (Null, A, B, and C) according to in vitro 21-hydroxylase activity as previously described. Genotype groups Null (n = 9) and A (n = 15) were predicted to result in SW CAH, group B (n = 8) was predicted to have the SV phenotype, and group C (n = 1) was predicted to have nonclassic CAH. A fifth group, D (n = 4), included patients in whom mutations were detected in only 1 allele. Plasma total metanephrine (420.1 +/- 60.0 vs. 657.7 +/- 67.8 pg/ml; P = 0.04) and free metanephrine (13.4 +/- 1.7 vs. 24.0 +/- 4.1 pg/ml; P = 0.008) concentrations were significantly lower in children with SW CAH than in those with the SV form of the disease. Plasma free metanephrine concentrations best predicted phenotype, with accuracy similar to that of genotype. Concordance rates between genotype and phenotype were higher in the most severely affected patients (Null, 88.9%; A, 93.3%; B, 75%; plasma free metanephrine, <18.5 pg/ml: SW, 92%). The plasma free metanephrine concentration correlated with the expected 21-hydroxylase activity based on genotype, and there was a significant trend for free metanephrine concentrations across the three genotype groups (P < 0.0001). Our findings indicate that measurement of adrenomedullary function, best assessed by the free metanephrine concentration, is a useful biomarker of disease severity in 21-hydroxylase deficiency. Molecular genotype and plasma free metanephrine concentration predict phenotype with similar accuracy. Both methods are more accurate in the most severe forms of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107196     DOI: 10.1210/jcem.87.7.8664

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency.

Authors:  Tony Huynh; Ivan McGown; David Cowley; Ohn Nyunt; Gary M Leong; Mark Harris; Andrew M Cotterill
Journal:  Clin Biochem Rev       Date:  2009-05

Review 2.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

3.  Adrenomedullary function in patients with nonclassic congenital adrenal hyperplasia.

Authors:  S Verma; L Green-Golan; C VanRyzin; B Drinkard; S P Mehta; M Weise; G Eisenhofer; D P Merke
Journal:  Horm Metab Res       Date:  2010-05-05       Impact factor: 2.936

Review 4.  Cortical-chromaffin cell interactions in the adrenal gland.

Authors:  Sven Schinner; Stefan R Bornstein
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 5.  Adrenal crises: perspectives and research directions.

Authors:  R Louise Rushworth; David J Torpy; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-19       Impact factor: 3.633

Review 6.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

7.  Mineralocorticoid deficiency and treatment in congenital adrenal hyperplasia.

Authors:  Raja Padidela; Peter C Hindmarsh
Journal:  Int J Pediatr Endocrinol       Date:  2010-05-04

Review 8.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Felix G Riepe; Wolfgang G Sippell
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

9.  Decreased adrenomedullary function in infants with classical congenital adrenal hyperplasia.

Authors:  Mimi S Kim; Anna Ryabets-Lienhard; Bhavna Bali; Christianne J Lane; Ashley H Park; Sandra Hall; Mitchell E Geffner
Journal:  J Clin Endocrinol Metab       Date:  2014-05-30       Impact factor: 5.958

10.  Blood Pressure and Left Ventricular Characteristics in Young Patients with Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Graziamaria Ubertini; Carla Bizzarri; Armando Grossi; Fabrizio Gimigliano; Lucilla Ravà; Danilo Fintini; Marco Cappa
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.